Orbital mucormycosis in an immunocompetent individual

Iranian Journal of Microbiology

Volumn 4, Issue 4, 2012, Pages 210-214

  Badiee, P ^a   Jafarpour, Z ^a   Alborzi, A ^a   Haddadi, P ^b   Rasuli, M ^a   Kalani, M ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amphotericin B; Immunocompetent; Mucormycosis; Orbital exentration

Indexed keywords

AMPHOTERICIN B; CEFTRIAXONE; CLINDAMYCIN; ITRACONAZOLE; VANCOMYCIN;

ARTICLE; CASE REPORT; CHEMOSIS; CHILD; COMPUTER ASSISTED TOMOGRAPHY; EXOPHTHALMOS; EYE REDNESS; EYE SWELLING; HUMAN; MALE; MUCORMYCOSIS; ORBIT CELLULITIS; ORBITAL MUCORMYCOSIS; PERIORBITAL CELLULITIS; PRESCHOOL CHILD;

ZYGOMYCETES;

EID: 84869026857     PISSN: 20083289     EISSN: 20084447     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Santos Gorjón P, Blanco Pérez P, BatuecasCaletrío A, Muñoz Herrera AM, Sánchez González F, de la Fuente Cañibano R. Rhino-orbito-cerebral mucormycosis, a retrospective study of 7 cases. Acta Otorrinolaringol Esp 2010; 61: 48-53.
2. Paulltauf A. Mycosis mucorina. Virchows Arch 1885.
3. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004; 45: 1351-1360.
4. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
5. Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (Mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15: 1395-401.
6. Albert DM, Lesser RL, Cykiert RC, Zakov ZN. Orbitofacial mucormycosis with unusual pathological features. Br J Ophthalmol 1979; 63: 699-703. British Journal of Ophthalmologybjo.bmj.com
7. Elinav H, Zimhony O, Cohen MJ, Marcovich AL, Benenson S. Rhinocerebralmucormycosis in patients without predisposing medical conditions: a review of the literature. Clin Microbiol Infect 2009; 15: 693-697.
8. Castón-Osorio JJ, Rivero A, Torre-Cisneros J. Epidemiology of invasive fungal infection. Int J Antimicrob Agents 2008; 32: 103-109.
9. Badiee P, Alborzi A, Farhoudi A. A case of Candida mediastinitis after dental extraction. J Infect Dev Ctries 2011; 5: 75-78.
10. Baezzat SR, Fazelzadeh A, Tahmasebi S, Kumar PV. Primary Breast Mucormycosis, a case report. Iran Red Crescent Med J 2011; 13: 208-209.
11. Yazdani J, Nezafati S, Arta SA, Ghavimi MA, Ghoreishizadeh A. Mucormycosis infection in a healthy patient. Medical Journal of Tabriz University 2011; 33 (4).
12. Shiva Prasad BN, Shenoy A, Nataraj KS. Primary gastrointestinal mucormycosis in an immunocompetent person. J Postgrad Med 2008; 54: 211-213.
13. Fairley C, Sullivan TJ, Bartley P, Allworth T, Lewandowski R. Survival after rhino-orbital-cerebral mucormycosis in an immunocompetent patient. Ophthalmology 2000; 107: 555-558.
14. O'Keefe M, Haining WM, Young JD, Guthrie W. Orbital mucormycosis with survival. Br J Ophthalmol 1986; 70: 634-636.
15. Martín-Moro JG, Calleja JM, García MB, Carretero JL, Rodríguez JG. Rhino orbito cerebral mucormycosis: a case report and literature review. Med Oral Patol 2008; 13: 792-795.
16. Gass JDM. Acute orbital mucormycosis. Report of two cases. Arch Ophthalmol 1961; 65: 214-220.
17. Badiee P, Alborzi A, Karimi M, Pourabbas B, Haddadi P, Mardaneh J, et al. Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients. J Infect Dev Ctries 2012; 6:352-327.
18. Badiee P, Alborzi A, Joukar M. Molecular assay to detect nosocomial fungal infections in intensive care units. Euro J Intern Med 2011; 22: 611-615.
19. Badiee P, Alborzi A. Assessment of a Real-time PCR method to detect human non-cryptococcal fungal meningitis. Arch Iran Med 2011; 14: 381-384.
20. Rickerts V, Just-Nubling G, KonraId F, Kern J, Lambrecht E, Bohme A, et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by semi-nested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis 2006; 25: 8-13.
21. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericinB-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-509.
22. Damante JH, Fleury RN. Oral and rhinoorbitalmucormycosis. J Oral Maxillofac Surg 1998; 56: 267-271.
23. Peterson KL, Wang M, Canalis RF, AbemayorE. Rhi nocerebralmucormycosis:evolution of the disease and treatment options. Laryngoscope 1997; 107: 855-862.
24. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J, Ibrahim AS: Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743-1751.
25. Yoon YK, Kim MJ, Chung YG, Shin IY. Successful treatment of a case with rhino-orbital-cerebral mucormycosis by the combination of neurosurgical intervention and the sequential use of amphotericin B and posaconazole. J Korean Neurosurg Soc 2010; 47: 74-77.
26. Reed C, Bryant R, Ibrahim AS, Edwards J, Filler SG, Goldberg R et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364-371.
27. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National institute of allergy and infectious diseases mycoses study group. N Engl J Med 1999; 340: 764-771.